The molecular pathogenesis of endotoxic shock and organ failure

被引:309
作者
Karima, R [1 ]
Matsumoto, S [1 ]
Higashi, H [1 ]
Matsushima, K [1 ]
机构
[1] Univ Tokyo, Fac Med, Bunkyo Ku, Dept Mol Prevent Med, Tokyo 113, Japan
来源
MOLECULAR MEDICINE TODAY | 1999年 / 5卷 / 03期
关键词
D O I
10.1016/S1357-4310(98)01430-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis is still associated with a high mortality rate, Septic shock and sequential multiple organ failure have a strong correlation with poor outcome. Lipopolysaccharide (LPS) plays a pivotal role in the initiation of host responses to Gram-negative infection. A number of mediators, such as cytokines, nitric oxide and eicosanoids, are responsible far most of the manifestations caused by LPS, and circulatory failure, leukocyte-induced tissue injury and coagulation disorder appear to be critical determinants in the development of sequential organ failure. Although several anti-LPS or anti-cytokine clinical trials have been attempted, none of them has so far been successful.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 60 条
[1]  
Abraham E, 1998, LANCET, V351, P929
[2]   p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].
Abraham, E ;
Glauser, MP ;
Butler, T ;
Garbino, J ;
Gelmont, D ;
Laterre, PF ;
Kudsk, K ;
Bruining, HA ;
Otto, C ;
Tobin, E ;
Zwingelstein, C ;
Lesslauer, W ;
Leighton, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538
[3]   Liposomal prostaglandin E(1) in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial [J].
Abraham, E ;
Park, YC ;
Covington, P ;
Conrad, SA ;
Schwartz, M .
CRITICAL CARE MEDICINE, 1996, 24 (01) :10-15
[4]   STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS [J].
ADERKA, D ;
ENGELMANN, H ;
MAOR, Y ;
BRAKEBUSCH, C ;
WALLACH, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :323-329
[5]   Interleukin-1 receptor antagonist: Role in biology [J].
Arend, WP ;
Malyak, M ;
Guthridge, CJ ;
Gabay, C .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :27-55
[6]   Predicting bacteremia in patients with sepsis syndrome [J].
Bates, DW ;
Sands, K ;
Miller, E ;
Lanken, PN ;
Hibberd, PL ;
Graman, PS ;
Schwartz, JS ;
Kahn, K ;
Snydman, DR ;
Parsonnet, J ;
Moore, R ;
Black, E ;
Johnson, BL ;
Jha, A ;
Platt, R .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1538-1551
[7]  
Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
[8]   INTERLEUKIN-10 IS A CENTRAL REGULATOR OF THE RESPONSE TO LPS IN MURINE MODELS OF ENDOTOXIC-SHOCK AND THE SHWARTZMAN REACTION BUT NOT ENDOTOXIN TOLERANCE [J].
BERG, DJ ;
KUHN, R ;
RAJEWSKY, K ;
MULLER, W ;
MENON, S ;
DAVIDSON, N ;
GRUNIG, G ;
RENNICK, D .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2339-2347
[9]   The effects of ibuprofen on the physiology and survival of patients with sepsis [J].
Bernard, GR ;
Wheeler, AP ;
Russell, JA ;
Schein, R ;
Summer, WR ;
Steinberg, KP ;
Fulkerson, WJ ;
Wright, PE ;
Christman, BW ;
Dupont, WD ;
Higgins, SB ;
Swindell, BB .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :912-918
[10]   A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL [J].
BONE, RC ;
BALK, RA ;
FEIN, AM ;
PERL, TM ;
WENZEL, RP ;
REINES, HD ;
QUENZER, RW ;
IBERTI, TJ ;
MACINTYRE, N ;
SCHEIN, RMH ;
TRENHOLME, G ;
NIEDERMAN, M ;
CHALFIN, D ;
ABALOS, A ;
OROPELLO, J ;
EMPSON, P ;
CAMINITII, S ;
GREENMAN, R ;
BOOTH, F ;
PLOUFFE, J ;
RUSSELL, J ;
GIANAKOPOULOS, G ;
IANNINI, P ;
HINDES, R ;
COBLENS, K ;
KOHLER, R ;
MARTIN, M ;
BERNARD, G ;
EDWARDS, J ;
CRISLIP, M ;
FILLER, S ;
NASRAWAY, SA ;
SIGEL, PK ;
SOTTILE, FD ;
MARTIN, DH ;
DEBOISBLANC, BP ;
CHANDRASEKAR, PH ;
BROUGHTON, WA ;
MIDDLETON, RM ;
SEIBERT, AF ;
EMMANUEL, G ;
LIE, TH ;
ANDERSON, CLV ;
PANKEY, GA ;
ANDERSON, P ;
OLSEN, K ;
SANPEDRO, GS ;
GRAHAM, D ;
GROSSMAN, J ;
WELS, PB .
CRITICAL CARE MEDICINE, 1995, 23 (06) :994-1006